拓扑替康对小细胞未分化肺癌住院患者的治疗作用  

Clinical study on the combination of topotecan (TPT) and DDP in the patients with small cell lung cancer

作　　者：穆海玉[1] 王春玲[1] 

机构地区：[1]佳木斯大学第一附属医院呼吸内科,黑龙江佳木斯154003

出　　处：《黑龙江医药科学》2003年第5期20-21,共2页Heilongjiang Medicine and Pharmacy

摘　　要：目的 :探讨盐酸拓扑替康联合顺铂治疗小细胞肺癌〔 SCL C〕的临床疗效和毒性。方法 :初治和复治的小细胞肺癌 34例。盐酸拓扑替康 0 .75 mg.〔m2 〕- 1 .d- 1 ,第 1～ 5天 ,每次静脉滴注 30 min;顺铂 30 m g.〔m2 〕- 1 .d- 1 ,第 1～ 3天 ,静脉滴注。4周为一周期 ,共 2个周期。结果 :在可评价疗效的 34例中 ,完全缓解〔 CR〕3例 ,部分缓解〔 PR〕19例有效率〔 RR〕6 4 .70 %。初治 2 8例 ,CR3例 ,PR16例 ,RR为 6 7.85 % .复治 6例 ,CR1例 ,PR2例 ,RR为 5 0 .0 0 %。局限期 2 9例 ,CR4例 ,PR16例 ,RR6 8.96 %。广泛期 5例 ,CR 0例 ,PR 2例 ,RR 4 0 .0 0 %。初治 RR高于复治 RR,P <0 .0 1;局限期 RR高于广泛期 RR,P<0 .0 1。大部分患者的症状明显改善。主要的毒副作用是骨髓抑制。结论 :盐酸拓扑替康联合顺铂是治疗小细胞肺癌的有效方案 ,其毒性反应可以耐受 。Objective: To evaluate the efficacy and safety of domestic topotecan (TPT) and DDP combination in treating small cell lung cancer(SCLC).Methods: Thirty four cases of previously treated and untreated SCLC patients were enrolled. Topotecan was given as 30 min intravenous infusion at 0.75m 2 daily for 3 day. The treatment was repeated once every 3 weeks. Efficacy was evaluated after two courses. Results: Thirty four patients went through the treatment schedule with 3 CR and 19 PR, with a total effective rate of 64.70%. Bone marrow suppresion was the dominate side effect. Conclusion: domestic TPT combinated with DDP is effective and safe for the treatment of SCLC, especially for recurrent cases.

关 键 词：拓扑替康 联合 顺铂 小细胞肺癌 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]